Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 17/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7521560 | 0.86 | HMGCR (0.57) | HMGCRMAPT | |
| SCHEMBL7083289 | 0.80 | HMGCR (0.65) | HMGCR | |
| Apomine SCHEMBL1648488 | 0.78 | HMGCR (1.00) | HMGCR | |
| SCHEMBL7080284 | 0.77 | HMGCR (0.60) | HMGCR | |
| SCHEMBL6370450 | 0.76 | HMGCR (0.54) | HMGCR | |
| SCHEMBL5662316 | 0.75 | FDPS (0.43) | HMGCRMAPTCYP1A2CYP2C19NPSR1 | |
| SCHEMBL624795 | 0.75 | FOS (0.50) | MAPTKMT2A | |
| SCHEMBL6320488 | 0.74 | L3MBTL1 (0.42) | HMGCRMAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21074678 | 0.74 | HMGCR (0.57) | HMGCR | |
| SCHEMBL7521921 | 0.73 | HMGCR (0.50) | HMGCRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482954-A4 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2005-06-09 | — | — | US | disclosed |
| EP-1482954-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | Ilex Products, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003069302-A2 | ALPHA-SUBSTITUTED ARYLALKYL PHOSPHONATE DERIVATIVES | ILEX PRODUCTS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124586-A1 | Alpha-substituted arylalkyl phosphonate derivatives | APOB, APOL1, LDLR | HMGCR 117/4885MAPT 4229/4885CYP1A2 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.